Literature DB >> 15027056

Central effects of botulinum toxin type A: evidence and supposition.

Antonio Currà1, Carlo Trompetto, Giovanni Abbruzzese, Alfredo Berardelli.   

Abstract

No convincing evidence exists that botulinum toxin type A (BT-A) injected intramuscularly at therapeutic doses in humans acts directly on central nervous system (CNS) structures. Nevertheless, several studies, using various approaches, strongly suggest that BT-A affects the functional organization of the CNS indirectly through peripheral mechanisms. By acting at alpha as well as gamma motor endings, BT-A could alter spindle afferent inflow directed to spinal motoneurons or to the various cortical areas, thereby altering spinal as well as cortical mechanisms. Muscle afferent input is tightly coupled to motor cortical output, so that the afferents from a stretched muscle go to cortical areas where they can excite neurons capable of contracting the same muscle. The BT-A-induced reduction in spindle signals could, therefore, alter the balance between afferent input and motor output, thereby changing cortical excitability. Copyright 2004 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15027056     DOI: 10.1002/mds.20011

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  27 in total

Review 1.  Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.

Authors:  Ying C Li; Ege T Kavalali
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

2.  Interneuronal Transfer and Distal Action of Tetanus Toxin and Botulinum Neurotoxins A and D in Central Neurons.

Authors:  Ewa Bomba-Warczak; Jason D Vevea; Joel M Brittain; Annette Figueroa-Bernier; William H Tepp; Eric A Johnson; Felix L Yeh; Edwin R Chapman
Journal:  Cell Rep       Date:  2016-08-04       Impact factor: 9.423

Review 3.  Botulinum toxin type A in motor nervous system: unexplained observations and new challenges.

Authors:  I Matak; Z Lacković; M Relja
Journal:  J Neural Transm (Vienna)       Date:  2016-09-01       Impact factor: 3.575

4.  Adult neuron addition to the zebra finch song motor pathway correlates with the rate and extent of recovery from botox-induced paralysis of the vocal muscles.

Authors:  Carolyn Pytte; Yi-Lo Yu; Sara Wildstein; Shanu George; John R Kirn
Journal:  J Neurosci       Date:  2011-11-23       Impact factor: 6.167

5.  No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm.

Authors:  C Lorenzano; S Bagnato; F Gilio; G Fabbrini; A Berardelli
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

6.  None detectable retrograde transport of Chinese botulinum toxin type A in mice by single intramuscular injection.

Authors:  Bin Hong; Lin-Lin Yao; Xing-Yue Hu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

7.  Hemifacial spasm non-motor and motor-related symptoms and their response to botulinum toxin therapy.

Authors:  Monika Rudzińska; Magdalena Wójcik; Andrzej Szczudlik
Journal:  J Neural Transm (Vienna)       Date:  2010-05-14       Impact factor: 3.575

Review 8.  Treatment and physiology in Parkinson's disease and dystonia: using transcranial magnetic stimulation to uncover the mechanisms of action.

Authors:  Aparna Wagle Shukla; David E Vaillancourt
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

9.  Autonomic cardiovascular function and baroreflex sensitivity in patients with cervical dystonia receiving treatment with botulinum toxin type A.

Authors:  D Tiple; S Strano; C Colosimo; G Fabbrini; G Calcagnini; M Prencipe; A Berardelli
Journal:  J Neurol       Date:  2008-05-07       Impact factor: 4.849

10.  Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A.

Authors:  Véronique Marchand-Pauvert; Claire Aymard; Louis-Solal Giboin; Federica Dominici; Alessandro Rossi; Riccardo Mazzocchio
Journal:  J Physiol       Date:  2012-10-08       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.